1. Home
  2. |Insights
  3. |Omission Of Claim Feature More Significant To Claim Interpretation Than That Feature's Inclusion In Specification Embodiment

Omission Of Claim Feature More Significant To Claim Interpretation Than That Feature's Inclusion In Specification Embodiment

Client Alert | 1 min read | 07.02.07

The Federal Circuit, in Saunders Group, Inc. v. Comfortrac, Inc., (No. 2006-1576, June 27, 2007), reverses and remands a district court’s grant of summary judgment finding noninfringement, after determining that the district court improperly limited the scope of certain claims to include a feature that was not recited in the claims. In so doing, the panel concludes that the change in claim language between the parent application and the continuation-in-part application, and the resulting inclusion of the particular claim feature in certain claims and its omission from other claims, “is a sufficiently powerful indicator as to the proper construction of the asserted claims that outweighs the portion of the specification in which the invention is described narrowly.” The claim construction issue is made particularly difficult, says the panel, by the failure of the applicants to expressly state to the examiner the extent to which they intended their new claims to depart from the scope of the claims in the predecessor applications.

Insights

Client Alert | 4 min read | 08.29.25

Gender-Affirming Care Targeted for Potential False Claims Act Enforcement

On August 19, 2025, the Office of Personnel Management (OPM) informed insurers participating in the Federal Employees Health Benefits or Postal Service Health Benefits programs that gender-affirming care would no longer be covered for federal workers starting in 2026. This coverage decision is the Trump Administration’s latest action stemming from Executive Order 14187 which aims to prevent certain treatments, such as gender-affirming hormone therapy, surgeries, and puberty blockers for those under the age of 19. As previously discussed, the Administration has also signaled its intent to use various law enforcement tools against gender-affirming care, including  Section 5 of the Federal Trade Commission Act to police false or unsupported claims by medical professionals about gender-affirming treatments....